Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Back to Search
Print
Bookmark Trial

NCT00437281

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Mobile, Alabama, 36604, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-16 month
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Partial onset seizures, incompletely controlled on 1-3 medications

- At least 1 seizure per 28 days, on average

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Primary generalized seizures


- Progressive CNS pathology

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Partial EpilepsiesDrug Use Investigation Of Gabapentin
NCT00567268
ALL GENDERS
0+
years
MULTIPLE SITES
Partial EpilepsiesA Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
NCT00620555
  1. Obu-shi,Morioka-machi, Aichi
  2. Jonan-ku, Fukuoka
  3. Kobe, Hyogo
  4. Suma-Ku,Kobe, Hyogo
  5. Kanazawa, Ishikawa
  6. Zentsuuji, Kagawa
  7. Yokohama, Kanagawa Pref.
  8. Sendai-shi, Miyagi-ken
  9. Showa-Ku, Nagoya
  10. Niigata-shi, Niigata
  11. Kurashiki-City, Okayama Pref.
  12. Okayama-shi, Okayama
  13. Izumi-shi, Osaka
  14. Miyakojima-ku, Osaka
  15. Suita, Osaka
  16. Shizuoka-shi, Shizuoka
  17. Kodaira, Tokyo
  18. Setagaya-ku, Tokyo
  19. Shinjuku-ku, Tokyo
  20. Hiroshima,
  21. Saitama,
  22. Yamagata,
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Partial EpilepsiesSafety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. Phoenix, Arizona
  4. Jonesboro, Arkansas
  5. Little Rock, Arkansas
  6. San Francisco, California
  7. Gulf Breeze, Florida
  8. Pensacola, Florida
  9. Tampa, Florida
  10. Tampa, Florida
  11. Springfield, Missouri
  12. Buffalo, New York
  13. Durham, North Carolina
  14. Houston, Texas
  15. San Antonio, Texas
  16. Seoul,
  17. Mexico, DF
  18. Guadalajara, Jalisco
ALL GENDERS
1 Month+
years
MULTIPLE SITES
Partial EpilepsiesSafety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)
NCT01441401
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
Official Title  ICMJE A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Brief Summary The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current medications.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Epilepsies, Partial
Intervention  ICMJE
  • Drug: Placebo
    Placebo
  • Drug: Pregabalin
    Orally-administered pregabalin
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Pregabalin
    Intervention: Drug: Pregabalin
Publications * Mann D, Liu J, Chew ML, Bockbrader H, Alvey CW, Zegarac E, Pellock J, Pitman VW. Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study. Epilepsia. 2014 Dec;55(12):1934-43. doi: 10.1111/epi.12830. Epub 2014 Nov 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 7, 2012)		65
Original Enrollment  ICMJE
 (submitted: February 16, 2007)		80
Actual Study Completion Date  ICMJE November 2012
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Partial onset seizures, incompletely controlled on 1-3 medications
  • At least 1 seizure per 28 days, on average

Exclusion Criteria:

  • Primary generalized seizures
  • Progressive CNS pathology
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Month to 16 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of,   Mexico,   United States
Removed Location Countries France
 
Administrative Information
NCT Number  ICMJE NCT00437281
Other Study ID Numbers  ICMJE A0081074
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP